Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

Exclusion Criteria

• •Seizure disorders not controlled by anticonvulsant therapy.
• •Known brain metastases (unless previously treated and well controlled for a period of greater than or equal to 3 months.)
• •Severe chronic obstructive pulmonary disease with hypoxemia or a pulmonary compromise not correctable with therapy.
• •Major surgery, other than diagnostic surgery, within 4 weeks prior to the first dose of test drug.
• •Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
• •Pregnant or nursing women.
• •Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within 4 weeks prior to study entry (6 weeks for nitrosoureas or Mitomycin C.)
• •Unwillingness or inability to comply with procedures required in this protocol.
• •Known infection with HIV, hepatitis B, or hepatitis C.
• •Clinically significant bleeding event within the last 3 months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis.
• •Patients who are currently receiving any other investigational therapy.
• •Patients who have exhibited allergic reactions to a similar structural compound (e.g., fluoroquinolones), biological agent, or formulation.